Antibodies as Drugs

抗体作为药物

• 批准号: 9042880
• 负责人: DAVID L. WOODLAND
• 金额: $ 0.7万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-02-10 至 2017-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9042880
• 关键词: Academia; Address; Antibodies; Area; Attention; Autoimmunity; Biology; British Columbia; Canada; Cancer Vaccines; Cell Therapy; Clinical; Collaborations; Communicable Diseases; Communities; Development; Diagnosis; Disease; Drug Approval; Drug Carriers; Drug Targeting; Engineering; Failure; Generations; Goals; Government; Head; Imaging technology; Immune system; Immunology; Immunotherapy; Industry; Inflammatory; Institutes; Investigation; Lead; Malignant Neoplasms; Medicine; Mission; Molecular; Monoclonal Antibodies; National Institute of Allergy and Infectious Disease; Oncogenes; Outcome; Pathway interactions; Pharmaceutical Preparations; Property; Protein Engineering; Radioisotopes; Research; Research Institute; Research Personnel; Scientist; Specificity; Staging; Structure; Students; Technology; Therapeutic; Therapeutic Human Experimentation; Therapeutic antibodies; Vaccine Research; Work; antibody engineering; base; cancer immunotherapy; cancer therapy; cytokine; imaging agent; improved; macromolecule; meetings; mimetics; next generation; oncology; posters; public health relevance; symposium

 DESCRIPTION (provided by the applicant): Support is requested for a Keystone Symposia meeting entitled Antibodies as Drugs, organized by Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup. The meeting will be held in Whistler, British Columbia, Canada from March 6-10, 2016. Monoclonal antibodies have had a pronounced impact in medicine and biology, with a broad array of approved agents that are used for the diagnosis, treatment and characterization of cancers, immunological disorders, and infectious diseases. Because of their exquisite target specificities, together with their favorable pharmacologic properties, antibodies are destined to have even increased clinical impact, particularly in diseases that are understood at the molecular level. This Keystone Symposia meeting will focus attention on many of the key advances in antibody-based technologies as well as on where the field is heading. Some of the critical topics that will be include: 1) Antibody structure and function; 2) Engineered antibodies and antibody-like molecules for improved efficacy; 3) Antibody pharmacologic properties and biologic distribution; 4) Antibody-based therapies for cancer and infectious diseases; 5) Targeting co-stimulatory pathways and immunological checkpoints; 6) Antibodies as carriers of drugs, cytokines, radioisotopes and imaging agents; 7) Antibody mimetics; and 8) Clinical advancements and challenges. This meeting has become an established forum that attracts both new investigators and leaders in the field, coming from academia, industry and research institutes around the globe. The goals of the meeting will be to address the critical issues facing the broad field of antibody-based therapeutics, provide an overview of recent advances and bring together interdisciplinary groups for the generation of new ideas and promising areas of investigation. Opportunities for interdisciplinary interactions will be significantly enhanced by te concurrent meeting on Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, which will share two plenary sessions with this meeting. The general topic of this meeting is relevant to the NIAID mission given the strong emphasis the meeting will have on immunological mechanisms for the treatment of cancer and other diseases.

 描述（由申请人提供）：请求支持由Peter D. Senter，安娜M.作者声明：John W.会议将于2016年3月6日至10日在加拿大不列颠哥伦比亚省惠斯勒举行。单克隆抗体在医学和生物学中具有显著的影响，具有广泛的用于癌症、免疫性疾病和感染性疾病的诊断、治疗和表征的批准试剂。由于其精确的靶特异性，以及其有利的药理学特性，抗体注定具有甚至更大的临床影响，特别是在分子水平上理解的疾病中。本次Keystone研讨会会议将重点关注基于抗体的技术的许多关键进展以及该领域的发展方向。其中包括：1）抗体的结构和功能; 2）用于提高疗效的工程抗体和抗体样分子; 3）抗体的药理学特性和生物学分布; 4）基于抗体的癌症和感染性疾病治疗; 5）靶向共刺激途径和免疫检查点; 6）抗体作为药物，细胞因子，放射性同位素和成像剂的载体; 7）抗体模拟物; 8）临床进展和挑战。这次会议已成为一个常设论坛，吸引了来自地球仪各地的学术界、工业界和研究机构的新的调查人员和该领域的领导人。会议的目标将是解决面临的关键问题， 基于抗体的治疗的广泛领域，提供了最新进展的概述，并汇集了跨学科小组，以产生新的想法和有前途的研究领域。跨学科互动的机会将大大加强了癌症疫苗：靶向癌症基因的免疫治疗，这将与本次会议分享两个全体会议同期会议。本次会议的主题是： NIAID的使命，因为会议将着重强调治疗癌症和其他疾病的免疫机制。